Electroskip Auditory Biofeedback in a Patient with Parkinson Disease: A Case Report by Szydlowski, Garrett et al.
Daemen College 
Daemen Digital Commons 
Faculty Articles Faculty Scholarship 
2019-10-28 
Electroskip Auditory Biofeedback in a Patient with Parkinson 
Disease: A Case Report 
Garrett Szydlowski 
Jamie O’Neil 
Jon Mrowczynski 
Lisa Inglis 
Michael Ross 
Follow this and additional works at: https://digitalcommons.daemen.edu/faculty_scholar 
 Part of the Physical Therapy Commons 
This is an Open Access article distributed under the terms of the Creative Commons At-
tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) 
which permits unrestricted non-commercial use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
Copyright © 2019 Korean Society of Exercise Rehabilitation http://www.e-jer.org pISSN 2288-176X
eISSN 2288-1778 
688
*Corresponding author: Garrett Szydlowski   https://orcid.org/0000-0002-4052-9633
Department of Physical Therapy,  Canisius College, 427 Wendel Ave, Buffalo,  
NY 14223, USA
E-mail: szydlowskigarrett@gmail.com
Received: July 6, 2019 / Accepted: July 28, 2019
Electroskip auditory biofeedback in a patient with 
Parkinson disease: a case report
Garrett Szydlowski1,2,*, Jamie O’Neil2, Jon Mrowczynski2, Lisa Inglis1, Michael Ross1
1Department of Physical Therapy, Daemen College, East Amherst, NY, USA
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The purpose of this case study was to observe the effects of a rehabili-
tation program with an audio-biofeedback technology device called 
Electroskip in a patient with Parkinson disease. The patient was a 
61-year-old man with moderate Parkinson disease (Hoehn and Yahr 
Parkinson’s scale stage III) and dementia who had progressive epi-
sodes of freezing of gait. The patient also had a history of recent falls. 
The patient completed a 6-week rehabilitation program focused on 
functional tasks, balance and gait training while using Electroskip tech-
nology, which is a wireless, wearable device that sends a discrete re-
al-time generative audio-biofeedback signal when the user steps on ei-
ther the heel or toe force sensors positioned under the innersoles. The 
outcome measures included the Timed Up and Go test, the modified 
Gait Abnormality Rating Scale, the modified Parkinson’s Activity Scale, 
and the Freezing of Gait Questionnaire. The patient completed 17 of the 
18 scheduled training sessions and all testing sessions; no adverse 
events occurred during the rehabilitation program and high satisfaction 
levels were reported by the patient and family after completion of the 
6-week rehabilitation program. Clinically significant improvements were 
seen in all measures at 6 weeks. The results of this report suggest that 
a rehabilitation program focused on functional tasks, balance, and gait 
training using the Electroskip technology may be beneficial for improv-
ing gait and balance in a patient with moderate Parkinson disease. Fu-
ture work is needed to determine the effectiveness of Electroskip tech-
nology by means of randomized controlled trials.
Keywords: Parkinson disease, Physical therapy, Electroskip
INTRODUCTION
Parkinson disease is defined as a progressive neuromuscular dis-
order that interferes with motor pathways within the central ner-
vous system (Kalia and Lang, 2015). Parkinson disease is the sec-
ond most common degenerative disease of the central nervous sys-
tem affecting 1% of the population above 60 years of age; it is 
predicted to increase in prevalence as the population ages (Beitz, 
2014; Tysnes and Storstein, 2017). Common clinical findings of 
Parkinson disease include tremors, rigidity, ceasing (or “freezing”) 
of volitional movements, hypokinesia, bradykinesia, decreased 
stability limits, and a festinating gait pattern classified by abnor-
mally slow shuffling steps with an anteriorly displaced center of 
mass (Massano and Bhatia, 2012). The “freezing of gait” phenom-
enon is a particularly debilitating component of Parkinson disease 
in which the voluntary muscle movements used to walk normally 
are inhibited, causing the patient to abruptly cease volitional 
movements in midstride (Heremans et al., 2013). This leads to an 
increased fall risk, negatively impacts independence, and conse-
quently decreases a patient’s overall quality of life. Therefore, the 
development of therapies with the goal of reducing the impacts of 
freezing episodes on gait is crucial to the well-being of the pa-
tients, their families, and society.
Biofeedback is the process of receiving information from the 
body’s normal functions, often with the aid of external electronic 
sensors. Auditory biofeedback utilizes sound for this purpose and 
the use of auditory biofeedback has demonstrated the ability to 
improve weight-bearing symmetry during gait for individuals 
with lower limb injuries (Isakov, 2007). Similarly, use of com-
bined somatosensory and audio-biofeedback for patients following 
a stroke has demonstrated the potential to improve step length, 
symmetry and speed significantly more than gait training with-
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out augmented feedback (Sungkarat et al., 2011). There is limited 
high-quality evidence supporting the use of rhythmic auditory 
cues to enhance walking speed for patients with Parkinson’s dis-
ease (Lim et al., 2005). Furthermore, it is unclear if the positive 
effects identified in the laboratory can subsequently lead to im-
proved activities of daily living and a reduction of falls in the 
community (Lim et al., 2005). In addition, the sustainability of a 
cueing training program remains uncertain. More recently, Mire-
lman et al. (2011) conducted a pilot study with seven patients 
with Parkinson disease utilizing an auditory biofeedback system 
in which the device was worn on the patient’s belt and attached to 
headphones by which the patient hears the auditory feedback. 
These researchers concluded that audio-biofeedback training was 
feasible and associated with improvements in balance for patients 
with Parkinson disease (Mirelman et al., 2011); however, research 
examining the utility of audio-biofeedback specific to gait train-
ing in this population is still quite limited (Gordt et al., 2018). 
Thus, there appears to be a need for further efforts in the area of 
rhythmic auditory cueing and its influence on gait and function 
in patients with Parkinson disease.
A recent device that was developed called Electroskip (Elec-
troskip LLC, Buffalo, NY, USA) produces real-time auditory bio-
feedback and a self-generated, trailing metronomic sound for the 
purpose of cueing a patient with Parkinson disease. The hardware 
itself is comprised of a wireless, wearable device that sends a dis-
crete signal when the user steps on either the heel or toe force sen-
sors. Electroskip is compatible with the musical instrument digi-
tal interface protocol allowing for a wide range of digital sounds, 
synthesizers or musical beats to be utilized. The metronome 
sound produced by the patient also adjusts in tempo-based upon 
the speed of the walker. This is significant as Electroskip not only 
generates instantaneous biofeedback, but also will serve as its own 
auditory cue for the following steps in the maintained time frame, 
which we hypothesize will address the gait speed abnormalities 
associated with the freezing of gait phenomenon of Parkinson dis-
ease. Therefore, the purpose of this case study was to explore the 
possible beneficial effects of a rehabilitation program with an au-
dio-biofeedback technology called Electroskip in a patient with 
moderate Parkinson disease.
MATERIALS AND METHODS
Participant
The patient was a 61-year-old man with moderate Parkinson 
disease (Hoehn and Yahr Parkinson’s scale stage III) (Hoehn and 
Yahr, 1967) who had progressive episodes of freezing of gait. In 
addition to Parkinson disease, which was diagnosed 3 years prior, 
his medical history included dementia, depression, and hyperten-
sion. The patient’s Parkinson disease was managed with carbido-
pa-levodopa 4 times daily. The patient was also taking donepezil 
hydrochloride for dementia, citalopram hydrobromide for depres-
sion, and hydrochlorothiazide for hypertension. In addition to 
progressive episodes of freezing gait, the patient had a history of 
greater than 3 falls per every 6 months span, decreased sitting and 
standing balance without support, decreased upper and lower ex-
tremity strength, poor motor control and muscle sequencing, de-
creased upper extremity range of motion, and difficulty with dy-
namic balance and gait activities. While the patient also had ver-
bal and cognitive deficits, he was alert, oriented to person and 
place, and he was able to follow commands necessary during reha-
bilitation to be an active participant in his therapy. He was ac-
companied by his daughter, father, and cousin, who gave written 
consent for participation in this case report and provided subjec-
tive information on his behalf. The patient lived with his elderly 
father on the first floor of a multiple story home. Family safety 
concerns included transferring to and from sitting to standing, 
transferring in and out of a vehicle, reaching overhead, stepping 
up/down from a curb, and safety during ambulation both indoors 
and outside.
Outcome measures
The outcome measures for gait and balance included the Timed 
Up and Go (TUG) test (Stegemöller et al., 2014), the modified 
Gait Abnormality Rating Scale (mGARS) (VanSwearingen et al., 
1996), the modified Parkinson’s Activity Scale (mPAS) (Keus et 
al., 2009), the Freezing of Gait Questionnaire (FOGQ) (Giladi et 
al., 2000), and the Berg Balance Scale (BBS) (Berg et al., 1995). 
These were selected as outcome measures based on their use in 
prior studies with either elderly patients (mGARS, BBS) (Berg et 
al., 1995; VanSwearingen et al., 1996) or with patients with Par-
kinson disease (TUG, mPAS, FOGQ, BBS) (Giladi et al., 2000; 
Keus et al., 2009; Stegemöller et al., 2014). Medication dose and 
timing remained constant over the course of treatment and out-
come measures were consistently obtained at the same time of day 
during the on phase of medication.
The TUG test is a timed trial assessing the time it takes for an 
individual to rise from a chair, traverse a 3-m distance, and return. 
This test was administered on testing day 1 and at the end of 6 
weeks. The patient’s timed averages were collected from 5 trials 
each under three conditions; shoes on but sound off, shoes on with 
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Electroskip audio-biofeedback, and shoes on with Electroskip au-
dio-biofeedback plus an accompanying background musical track. 
Rest was given as needed to the patient and full recovery was en-
sured prior to proceeding to the next test trial. The order of the 
testing conditions was random on day 1 and at week 6. Every trial 
throughout the study began with the physical therapist position-
ing the patient in optimal sitting posture with consistent verbal 
directions for completion of the TUG task.
The mGARS and mPAS were administered at three points 
during the course of care: day 1, week 3, and week 6. The mGARS 
is a physical therapist scored tool in which lower scores reflect a 
more normalized gait pattern through observation of a 15.2-m 
walk and graded on certain criteria such as heel contact and vari-
ability of movements (VanSweringen et al., 1996). The mPAS 
(gait akinesia section specifically) is a physical therapist scored as-
sessment in which the patient must stand up, walk a 3-m U-shaped 
pattern, and return to sitting under 3 conditions (i.e., without ex-
tra task, with dual task, with cognitive task), in which higher 
scores correspond with improved performance (Keus et al., 2009). 
Two trials, with and without the Electroskip audio-biofeedback, 
were performed at each testing trial. The order of testing was re-
versed at week 3 to limit effects of fatigue and learning. Both tools 
were scored by the lead author and then reviewed by the patient’s 
caregivers to ensure accuracy and to minimize bias. The mPAS 
was not used in full, but limited to the section pertaining to gait 
akinesia as the other sections were not relevant to this case.
The FOGQ is a 6-question survey reflecting how freezing epi-
sodes impact a person’s gait and daily activities, in which lower 
scores are optimal (Giladi et al., 2000). The FOGQ, appendix B 
specifically, showed a strong correlation between scores achieved 
and quality of life amongst patients with Parkinson disease (Ellis 
et al., 2011). The FOGQ was given to the patients’ caregivers to 
complete due to the patient’s cognitive function. The question-
naire was completed on day 1, week 3, and week 6, with instruc-
tions to complete the form twice, reflecting on gait behaviors ob-
served both with and without the Electroskip technology active 
during the sessions.
The BBS is a commonly used functional balance assessment 
tool designed to identify fall risk in community-dwelling older 
adults (Berg et al., 1995). It is considered the reference standard, 
and its use as a functional balance tool for individuals with neuro-
logic conditions, including patients with Parkinson disease, has 
been well documented (Qutubuddin et al., 2005; Taghizadeh et 
al., 2018).
Intervention
The patient was scheduled for 3 physical therapy visits per week 
for 6 weeks in addition to 3 additional testing days on day 1, week 
3, and again at week 6. This visit schedule is consistent with Mi-
relman et al. (2011), who assessed the effects of an auditory bio-
feedback system to augment an individualized training program 
on balance in patients with Parkinson disease. Physical therapy 
visits were 45 min and consisted of upper extremity and trunk 
stretching, followed by upper extremity and trunk strengthening, 
and concluded with functional task training (e.g., step-ups, sit-to-
stand transfers, standing, kicking) and gait training (forward, back-
ward, side stepping, turning, dual task [counting], step length 
cueing, arm swing normalization). Gait training utilized Electroskip 
technology, which is a wireless, wearable device that sends a dis-
crete real-time generative audio-biofeedback signal when the user 
steps on either the heel or toe force sensors positioned under the 
innersoles (Fig. 1). Additionally, a self-generated metronomic sound 
adjusts in tempo-based upon the speed of the walker, serving as 
an auditory cue. The device is used by attaching two pressure sen-
sors underneath the innersoles of the patient’s shoes (Fig. 2). A 
transmitter attached to the shoelaces sent wireless pulses from the 
sensors to a computer with audio software in order to convert the 
signals into audio. The biofeedback sounds were in harmony with 
three of the patient’s favorite songs, and the background music 
Fig. 1. Electroskip technology attachment to shoes. Fig. 2. Electroskip sensor positioning under toes and heel.
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was included as an optional feature. When the patient would per-
form typical functional training, Electroskip would produce the 
selected tonal patterns in a steady, trailing metronomic fashion. 
The patient was asked to place emphasis on fluid motions that 
would produce a continuous and rhythmic audio-biofeedback re-
sponse. The background music tracks would be used as seen fit by 
the therapist in order to encourage initiation of movement and 
participation.
RESULTS
The patient completed 17 of the 18 scheduled training sessions 
and all testing sessions; high satisfaction levels were reported by 
the patient and family after completion of the 6-week rehabilita-
tion program. No adverse events occurred during the rehabilita-
tion program and no falls were reported outside of the clinic by 
the patient or his caregivers. On day 1, the TUG test improved 
from 53 sec to 39 sec with the use of Electroskip technology. At 6 
weeks, the TUG test was 24 sec and 23 sec with and without the 
use of Electroskip technology, respectively. The scores on the 
TUG test with the use of Electroskip technology with back-
ground music were slightly longer than with the use of Elec-
troskip technology alone (Fig. 3). For the mGARS, scores on day 
1 were 3.5/21 with the Electroskip technology and 5.5/21 with-
out the Electroskip technology. Scores under both conditions im-
proved to 2/21 by week 6 (Fig. 4). For the mPAS, the score was 
19 on day 1, 23 at 3 weeks and 21.5 at 6 weeks without Elec-
troskip technology; with the use of Electroskip technology, the 
mPAS increased to 23 on day 1 and at 3 weeks, and 23.5 at 6 
weeks (Fig. 5). For the FOGQ, the score without the Electroskip 
technology was 14 on day 1 and it remained at 14 at weeks 3 and 
6; with the use of Electroskip technology, the FOGQ decreased to 
6 at weeks 3 and 6 (Fig. 6). The BBS improved from 39 days 1 to 
48.5 at week 6, however, Electroskip technology was not used 
during assessment with the BBS.
Fig. 4. The patient’s modified Gait Abnormality Rating Scale (mGARs) scores 
comparing weeks 1, 3, and 6 with and without the use of Electroskip technology.
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Fig. 5. The patient’s modified Parkinson’s Activity Scale (mPAS) scores compar-
ing weeks 1, 3, and 6 with and without the use of Electroskip technology.
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Fig. 3. The patient’s mean Timed Up and Go test results comparing week 1 to 
week 6. The “no sound” condition refers to test performance without the use 
of Electroskip technology or background music. The “just skips” condition re-
fers to test performance with the use of Electroskip technology and no back-
ground music. The “music and skips” condition refers to test performance with 
the use of Electroskip technology and background music. The vertical lines in 
the middle in each column represent the range of scores for each test trial.
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DISCUSSION
The purpose of this case study was to explore the possible bene-
ficial effects of a rehabilitation program with an audio-biofeed-
back technology (e.g., Electroskip) in a patient with moderate 
Parkinson disease. For the patient described in this case report, we 
hypothesized that Electroskip technology would address the gait 
speed abnormalities associated with the freezing of gait phenome-
non of Parkinson disease.
This hypothesis was based upon the limited reports that have 
described some usefulness of audio-biofeedback with gait training 
in patients with Parkinson disease (Gordt et al., 2018; Lim et al., 
2005; Thaut et al., 1996). Thaut et al. (1996) evaluated the effect 
of rhythmic auditory stimulation on various aspects of gait follow-
ing a 3-week home-based gait-training program for patients with 
Parkinson disease. Patients who participated in the gait-training 
program with rhythmic auditory stimulation significantly im-
proved their gait velocity by 25%, stride length by 12%, and step 
cadence by 10% more than patients who participated in a self-
paced gait-training program not supplemented with rhythmic 
auditory stimulation, whose gait velocity improved by 7%, and 
patients who did not participate in a gait-training program, 
whose gait velocity decreased by 7%. Additionally, some features 
of the gait cycle as profiled with electromyography changed to-
ward more normal muscle activation patterns for those patients 
who participated in the gait-training program with rhythmic au-
ditory stimulation (Thaut et al., 1996). In our case, we did not 
formally assess gait parameters such as velocity, stride length, or 
step cadence or electromyographic activity during gait. Nonethe-
less, after 6 weeks of training with Electroskip technology, which 
combines rhythmic auditory stimulation with audio-feedback, 
our results seem to reflect those of Thaut et al. (1996), as improve-
ments were observed across all testing conditions (with and with-
out the technology active) in the majority of outcome measures 
used that dealt with gait. Thus, our hypothesis was generally sup-
ported.
High-quality evidence on the effects of external rhythmical 
cueing on gait in patients with Parkinson disease is limited. Fur-
thermore, it is unclear whether the limited positive effects identi-
fied in the laboratory can be generalized to clinical rehabilitation 
programs with subsequent improved activities of daily living and 
reduced frequency of falls in the community (Lim et al., 2005). 
However, the results of this case report suggest potential immedi-
ate and short term (i.e., 6 weeks) positive therapeutic effects from 
the use of the Electroskip audio-biofeedback technology. While 
the patient described in this case report had verbal and cognitive 
deficits, he was alert, oriented to person and place, and he was able 
to follow commands necessary during rehabilitation to be an ac-
tive participant in his therapy. The patient in this report subse-
quently performed better in every outcome during measurements 
taken on the first day while the technology was in use, suggesting 
that the patient’s motor skills received an immediate benefit from 
the cueing and biofeedback generated by the metronome-like 
sound of the Electroskip. After 6 weeks of participation in a reha-
bilitation program augmented with Electroskip technology, im-
provements were observed across all testing conditions in the ma-
jority of outcome measures used; this was most notable in the 
TUG test and mGAR scores (Figs. 3 and 4). This implies that the 
Electroskip technology may also have some benefit when used in 
a clinical setting for achievement of long-term rehabilitation 
goals. Electroskip technology, therefore, may offer a potential 
combination of immediate and short term (i.e., 6 weeks) clinical 
benefits that warrant further research into the treatment of motor 
impairments in patients with Parkinson disease.
For the mPAS scores, there was slightly improved performance 
noted with the Electroskip technology turned on in both weeks 1 
and 6 (Fig. 5) compared to when the Electroskip technology was 
turned off. At week 3, however, the scores did not differ between 
those same conditions. Scores achieved without the use of the 
Electroskip technology increased from week 1 to 3, and then 
slightly decreased at week 6. Scores achieved with the Electroskip 
technology active showed little variation, however; they were al-
ways the same or superior when compared to the scores seen with-
out non-Electroskip technology. The condition of the mPAS in 
Fig. 6. The patient’s the Freezing of Gait Questionnaire (FOGQ) scores compar-
ing weeks 1, 3, and 6 with and without the use of Electroskip technology.
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which improvement was most notable when the Electroskip tech-
nology was enabled was when the patient was asked to perform a 
dual cognitive counting task while navigating the 3-m U-shaped 
pattern. The audio-feedback associated with the device appeared 
to decrease the cognitive demands on the pacing of the motor 
component of this task, thus allowing for the counting task to be 
performed with greater ease. Additionally, given the results from 
the other outcome measures, Electroskip technology enhanced the 
patient’s ability to perform smooth, voluntary motions with an 
immediate increase in ambulation and turning speed; the 6-week 
training program produced further improvements observable un-
der all conditions.
The BBS scores from before and after the 6-week data collection 
period were included as supplemental data to further evaluate the 
Electroskip technology. Within the month prior to beginning 
data collection, the patient scored a 39 with their prior physical 
therapy program. This score increased to 48.5 after 8 weeks, 
which encompassed the entire 6-week duration of this study. Our 
results with respect to improvements in the BBS are generally 
consistent with those of Mirelman et al. (2011), who reported sig-
nificant improvements in the BBS following a 6-week individual-
ized training program that was augmented with auditory biofeed-
back in 7 patients with Parkinson disease. More specifically, Mire-
lman et al. (2011) reported positive trends in all measures of bal-
ance control in response to the training when subjects were as-
sessed after the conclusion of the 6-week program. The BBS sig-
nificantly improved by 3% (P=0.032) (mean pretraining 
score=49.0±7.2; mean posttraining score=50.4±6.7) and al-
though not statistically significant, the TUG test scores and time 
to perform 5 sit-to-stand maneuvers improved by 11% (P=0.07) 
and 7.3% (P=0.09), respectively. These results suggest that over-
all balance performance may be improved following an individu-
alized training program that has been augmented with auditory 
biofeedback in patients with Parkinson disease. Future trials with 
the Electroskip technology, or other forms of auditory biofeed-
back, should continue to include the BBS as a formal performance 
measure for more conclusive findings.
Previous research has demonstrated that visual, vibratory and 
auditory cueing can be effective means of overcoming a freezing 
episode (Velik, 2012). Cues that are both continuous and relevant 
to the action of stepping, such as those produced by the Elec-
troskip, have also been found to delay the onset of freezing by en-
gaging sensorimotor circuitry and bypassing the basal ganglia 
(Young et al., 2016). The potential to use auditory cues for more 
lasting improvements was investigated by Plotnik et al. (2014), 
who trained individuals with Parkinson disease to respond to 
rhythmic auditory stimulation immediately prior to stimuli 
known to trigger freezing episodes and demonstrated reduced ep-
isodes of freezing, improved gait speed and performance even 
when cues were removed. While this type of motor learning 
training may be beneficial, it requires extensive set-up of the envi-
ronment to produce triggered stimulation. By combining this 
type of auditory stimulation with audio-biofeedback and translat-
ing this intervention into a wearable technology, the Electroskip 
was able to yield similar reductions in freezing episodes while 
wearing a device that was highly portable and worked flexibly 
within the clinic environment. Improvements in freezing, in this 
case, were not found to persist when the device was turned off as 
they did in previous investigations; however, it is likely the sub-
ject’s cognitive involvement limited his potential for motor learn-
ing. The subject did demonstrate improvements in gait speed on 
the TUG test over the course of treatment using the Electroskip 
that persisted when the device was removed. Walking with rhyth-
mic auditory cueing has been previously found to improve gait 
cadence, velocity and stride length (Spaulding et al., 2013) and 
the results of this case study indicate that repeated training with 
audio-biofeedback during gait may have a similar beneficial train-
ing effect that can carry over to uncued gait.
There are some limitations to this report that should be consid-
ered. First, because this was a single subject case report, cause and 
effect cannot be inferred and the conclusions that can be drawn are 
limited. Observable benefits may not be generalizable to other pa-
tient populations. Second, considerable care was taken to develop 
the testing protocol in an individual with freezing episodes and 
great variability in gait. However, we are not completely sure of 
the effect of fatigue and motor learning on our testing protocol. 
Furthermore, placebo response rates may be high for patients with 
Parkinson disease (Diederich and Goetz, 2008). Subsequent trials 
are needed to determine optimal testing strategies that control for 
fatigue and motor learning factors, as well as possible placebo ef-
fects. However, a case series or a small open-label trial would have 
clinical merit and could serve as the next logical step for investi-
gating the effects of Electroskip technology. Third, the patient 
had limited verbal and writing/reading comprehension skills, 
which likely interfered with a true self-assessment on the FOGQ. 
For this reason, the patient’s caregivers completed the instrument 
to the best of their ability and in agreement with one another. 
This strategy may not be optimal to assess true gait improve-
ments, especially when they were asked to reflect on gait behav-
iors observed with the Electroskip technology active during the 
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sessions, as the FOGQ is typically completed based of freezing be-
havior in past week. Additionally, the Electroskip technology was 
unavailable to the patient at home, so any comparisons of the pa-
tient’s gait with and without the technology on had to be done at 
similar times of the day and under similar circumstances to ensure 
accuracy and thus, may not reflect home use performance or the 
influence of the technology on activities of daily living.
In conclusion, the results of this case report suggest that a reha-
bilitation program focused on functional tasks, balance, and gait 
training using the Electroskip technology may be beneficial for 
improving gait and balance in a patient with moderate Parkinson 
disease. Future work is needed to determine the effectiveness of 
Electroskip technology by means of randomized controlled trials.
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